European Heart Journal Advance Access originally published online on October 4, 2005
European Heart Journal 2005 26(24):2673-2680; doi:10.1093/eurheartj/ehi556
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Does implementation of the European guidelines based on the SCORE model double the number of Norwegian adults who need cardiovascular drugs for primary prevention? The Tromsø study 2001
1Department of Pharmacy, University of Tromsø, N-9037 Tromsø, Norway
2Department of Community Medicine, University of Tromsø, N-9037 Tromsø, Norway
Received 14 April 2005; revised 5 September 2005; accepted 8 September 2005; online publish-ahead-of-print 4 October 2005.
* Corresponding author. Tel: +47 977 03853; fax: +47 77 64 66 47. E-mail address: ingeborg{at}farmasi.uit.no
See page 2605 for the editorial comment on this article (doi:10.1093/eurheartj/ehi596)
Aims To study the implications of European guidelines on the use of antihypertensives and/or lipid-lowering drugs (LLDs) for primary prevention in a Norwegian population.
Methods and results The Tromsø study is a population-based study in the municipality Tromsø, Norway (from 1974 to till now). This analysis includes 45–79-year-old participants in 2001 (n=6362, attendance rate 86%). From the age of 60 years in men and 70 years in women, almost all participants were defined as high-risk individuals according to the European guidelines, with established cardiovascular disease, diabetes, or a 10-year risk score of 
5%. In the primary prevention subgroup of the 45–64-year-olds, recommended antihypertensive and/or LLD use would be higher in men only, 42% compared with 12% on current medication. Among the 65–79-year-olds, >90% would be eligible for antihypertensives and/or LLDs in both sexes when compared with current treatment rates of <30%. In total, 40% of all participants aged 45–79 would be candidates for primary prevention, compared with 15% on current medication.
Conclusion The implementation of the European guidelines could imply a doubling of the numbers of Norwegian adults on cardiovascular medication for primary prevention. Contributors to the increase would be more frequent drug use in men and elderly people, particularly for LLD use.
Key Words: Cardiovascular disease • Guidelines • Primary prevention • Lipid-lowering drugs • Antihypertensives • Risk assessment
CiteULike 
Connotea 
Del.icio.us What's this?
Related articles in EHJ:
- Who wants to be normal?
- Staffan Lindeberg
EHJ 2005 26: 2605-2606.[Extract] [FREE Full Text]
This article has been cited by other articles:
|
|
 |
|
  S. Hallan, B. Astor, S. Romundstad, K. Aasarod, K. Kvenild, and J. Coresh Association of Kidney Function and Albuminuria With Cardiovascular Mortality in Older vs Younger Individuals: The HUNT II Study Arch Intern Med, December 10, 2007; 167(22): 2490 - 2496. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lindeberg Who wants to be normal? Eur. Heart J., December 2, 2005; 26(24): 2605 - 2606. [Full Text] [PDF]
|
|